🔗 Share this article

As America continues making unprecedented revisions to its vaccination schedules, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who initially gained attention by questioning Covid shots during the pandemic and has zeroed in on possible deaths after Covid immunization in her short position at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Program

Agency leaders planned to announce major changes to the childhood vaccine schedule recently, aligning the US with the Danish national calendar, it is understood – a major change that would put the US out of step with much of the international standard with no evidence for improved outcomes. The announcement has been postponed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to speak at the event. She was just designated interim head of the FDA’s CDER, the fifth individual to head the division this calendar year.

A New Direction at the Agency

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

The new acting director has repeatedly called for halting specific pediatric immunization guidelines in the US so as to align more similar to Denmark's approach, a society with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on immunizations – traditionally the domain of Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Doubts Over Qualifications

Høeg has little discernible experience in medication creation, regulation or leadership, which has been customary for former leaders of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since March.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in leading a large organization. She is not an expert in drug approvals.”

Past heads of the center would “grasp legal statutes and the research of drug development”, commented a former acting FDA commissioner. “Objectively, she lacks the sort of resume that former directors who led CBER have had.”

The drug center has an enormous range of responsibilities at the agency, the former commissioner emphasized.

“Everybody just focuses on the new drug program, but the generic drug division approves a multitude of generic drugs. There’s a biosimilars program, over-the-counter program and other areas, and all of those have to be looked after,” Woodcock noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership element to the position, which supervises more than 5,000 personnel. “It is a enormous administrative position, if you execute it properly,” the former official concluded.

Agency Reaction and Disputed Policies

Regarding concerns about Dr. Høeg's fitness for the role and whether this selection represents more teamwork among regulatory chiefs on vaccines, a representative said that the “inquiries rely on flawed presumptions”.

“Her experience matches the responsibilities of her job,” the representative explained, noting the time Dr. Høeg spent guiding the agency head on “drug safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new priority voucher program, a contentious rapid therapy clearance system that apparently troubled her former heads. “How are these drugs being selected for this fast-track system? Who makes the calls?” Howard questioned. “There’s a lot of confidentiality happening at the agency right now.”

Broadly speaking, he stated, “the FDA looks to be trending towards laxer oversight of most medications, except for shots.”

Established History on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if concerning, track record, some experts said. She authored a study using non-validated crowd-sourced reports to assess the rate of heart inflammation after Covid immunization. She advised the state of Florida top health official Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the current administration encompassed revising guidelines for recently developed shots and halting “non-essential” immunizations, she remarked following the vote on a podcast. At the agency, Høeg has according to sources floated the idea of excluding adolescent males from receiving COVID-19 vaccinations.

“She’s an all-around ideologue who starts off with her beliefs and works backwards to retrofit the evidence in a extremely misleading, untruthful way,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg aligned with fellow skeptics, {like|